Daratumumab has reshaped multiple myeloma treatment over the past several years, moving from a later-line rescue therapy to a guideline-recommended backbone drug used even in newly diagnosed patients — a shift in clinical practice that's directly driving up global demand and, correspondingly, our export volume for this product. It targets CD38, a protein highly expressed on myeloma cells, marking them for destruction through several complementary immune mechanisms simultaneously rather than relying on a single mode of action.

• Approved indications: Multiple myeloma — newly diagnosed patients (both transplant-eligible and ineligible) and relapsed/refractory disease
• Mechanism: Targets CD38 on myeloma cells, triggering cell death through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis
• Combination regimens: Frequently combined with bortezomib, lenalidomide, or dexamethasone-based standard-of-care regimens rather than used as monotherapy
• Clinical trend driving demand: Increasing adoption in first-line, newly diagnosed myeloma treatment (not just relapsed cases) is significantly expanding the eligible patient population and, with it, global sourcing demand

Daratumumab carries two precautions that are less about the patient's direct clinical risk and more about coordination with other parts of the hospital system — both are easy to miss if a receiving facility hasn't handled the drug before, which is why we flag them proactively with every new institutional buyer.

• Infusion reactions: Very common, particularly with the first infusion — a structured pre-medication protocol (antihistamine, antipyretic, corticosteroid, and often montelukast) is standard and non-negotiable
• Blood bank interference (critical operational note): Daratumumab binds CD38 on red blood cells as well as myeloma cells, which interferes with standard blood-bank crossmatch testing for up to 6 months after the last dose — hospital blood banks must be informed before a patient starts treatment, or transfusion compatibility testing can be significantly delayed in an emergency
• Hepatitis B reactivation risk: Screening recommended in patients with prior Hepatitis B exposure before starting treatment

Stock status: On request | Quote turnaround: Confirm strength and destination for verified pricing

• Logistics: GDP-compliant cold-chain export (2–8°C, protect from light)
• Coverage: Global markets, with meaningfully expanding demand from LATAM and Africa as myeloma diagnosis rates and treatment access both increase
• Tracking: Full shipment tracking included

What is Daratumumab used for?

Treats multiple myeloma, both newly diagnosed and relapsed cases, usually combined with drugs like bortezomib or lenalidomide.

Get Daratumumab price from a GMP-compliant Indian supplier — how?

Send strength and destination for a verified export quote.

Does it affect blood transfusions?

Yes, it interferes with standard blood-bank compatibility testing for up to 6 months after the last dose — hospitals must be informed in advance.

Can it be combined with other myeloma drugs?

Yes, it's commonly combined with bortezomib, lenalidomide, or dexamethasone-based regimens.

Who supplies Daratumumab from India?

WHO-GMP certified manufacturing partners with full export documentation.